Clinical Trial Update: MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating MR-guided adaptive SBRT of the primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Snippet

Sponsor: Ludwig-Maximilians - University of Munich | Conditions: Pancreatic Cancer | Phase 2 | Status: TERMINATED